Your Yourlocation: Home > Studing the using of tiotropium bromide(136310-93-5)

The investigators performed a series of pretreatments, including the initiation of tiotropium bromide(136310-93-5) during a lead-in period of at least 8 days, and pretreatment of bronchoscopy.

Throughout the course of treatment, the researchers used bronchoscopy and fluorescence imaging to guide the electrode positioning.

Each patient was treated in two phases at intervals of 30 days. Patients were not treated with drugs and discontinued after treatment with tiotropium bromide(136310-93-5).

Of the 20-watt ablation patients, 1 withdrew from the treatment and the remaining 11 achieved the primary end point of the study "There was no persistent deterioration of lung resistance due to TLD treatment within 1 year.19 Of the 10 patients who received the 15-watt ablation group, Also achieved this effect, the overall compliance rate was 95%.

Although none of the patients died, 7 patients had severe post-treatment adverse events including chronic obstructive pulmonary disease (COPD), allergic drug reactions, coronary artery bypass grafting (CABG), chest pain, and gastroparesis. Four of these events occurred in the same patient.

No device-related adverse events occurred in this procedure.

The feasibility of the process was 93%.

Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved